ArticleOpen forum infectious diseases2021
Assessment of Antibiotic De-escalation by Spectrum Score in Patients With Nosocomial Pneumonia: A Single-Center, Retrospective Cohort Study.
Article in Open forum infectious diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- The emergence and biological characteristics of linezolid-resistantEmerging microbes & infections · 2026Article
- Evaluation of the clinical impact of de-escalated versus non-de-escalated antibiotics for the treatment of methicillin-susceptible staphylococcus aureus pneumonia in critically ill patients admitted to intensive care units: a multicenter cohort study.BMC infectious diseases · 2026Article
- Clinical impact of a commercial multiplex pathogen panel for the detection of bacteria in sputum specimens from non-ICU patients with suspected lower respiratory tract infection.Antimicrobial stewardship & healthcare epidemiology : ASHE · 2026Article
- Comparison of Spectrum Coverage Score-based Antimicrobial Consumption in Acute Care Hospitals Over Eight Years: A Multicentric Study.Open forum infectious diseases · 2025Article
- Antibiotic De-Escalation in the Intensive Care Unit: Rationale and Potential Strategies.Antibiotics (Basel, Switzerland) · 2025Review
- Korean Guidelines for the Management and Antibiotic Therapy in Adult Patients with Hospital-Acquired Pneumonia.Tuberculosis and respiratory diseases · 2025Article
- Feasibility and utility of the days of antibiotic spectrum coverage (DASC) in national antimicrobial use surveillance in Japan.Antimicrobial stewardship & healthcare epidemiology : ASHE · 2025Article
- Assessment of antibiotic utilization patterns in an Indian Level-1 Trauma Center: a pilot study exploring days of antibiotic spectrum coverage and defined daily doses using WHO AWaRe classification trends.Frontiers in antibiotics · 2025Article
- Preoperative Antibiotic Administration Does Not Improve the Outcomes of Operated Diabetic Foot Infections.Antibiotics (Basel, Switzerland) · 2024Article
- Simplified Spectrum Score (SScientific reports · 2024Article
- Days of Antibiotic Spectrum Coverage Trends and Assessment in Patients with Bloodstream Infections: A Japanese University Hospital Pilot Study.Antibiotics (Basel, Switzerland) · 2022Article
- Short and Concise Peer-to-Peer Teaching-Example of a Successful Antibiotic Stewardship Intervention to Increase Iv to Po Conversion.Antibiotics (Basel, Switzerland) · 2022Article
- Lack of pathogen identification influencing antibiotic de-escalation in hospital-acquired pneumonia.Antimicrobial stewardship & healthcare epidemiology : ASHE · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHospital-acquired and ventilator-associated pneumonia (HAP/VAP) cause significant mortality. Guidelines recommend empiric broad-spectrum antibiotics followed by de-escalation (DE). This study sought to assess the impact of DE on treatment failure.
methodsThis single-center retrospective cohort study screened all adult patients with a discharge diagnosis code for pneumonia from 2016 to 2019. Patients were enrolled if they met predefined criteria for HAP/VAP ≥48 hours after admission. Date of pneumonia diagnosis was defined as day 0. Spectrum scores were calculated, and DE was defined as a score reduction on day 3 versus day 1. Patients with DE were compared to patients with no de-escalation (NDE). The primary outcome was composite treatment failure, defined as all-cause mortality or readmission for pneumonia within 30 days of diagnosis.
resultsOf 11860 admissions screened, 1812 unique patient-admissions were included (1102 HAP, 710 VAP). Fewer patients received DE (876 DE vs 1026 NDE). Groups were well matched at baseline, although more patients receiving DE had respiratory cultures ordered (56.6% vs 50.6%,
conclusionsDe-escalation and NDE resulted in similar rates of 30-day treatment failure; however, DE was associated with fewer antibiotic days, episodes of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.